Michael Fischbach

Prof. Michael Fischbach is a Professor of Bioengineering at Stanford University, an Institute Scholar of Sarafan ChEM-H, and Director of the Stanford Microbiome Therapies Initiative. In his role at the Stanford Innovative Medicines Accelerator (IMA), Fischbach shapes the development of first-in-class therapeutics.

Prof. Fischbach received his PhD as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007, where he studied the role of iron acquisition in bacterial pathogenesis and the biosynthesis of antibiotics. After two years as an independent fellow at Massachusetts General Hospital, Prof. Fischbach joined the faculty at UCSF, where he founded his lab before moving to Stanford in 2017. His laboratory studies the mechanisms of microbiome-host interactions. He is a recipient of the NIH Director’s Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, and the Vannevar Bush Faculty Fellowship. Prof. Fischbach is a co-founder of Kelonia and Revolution Medicines, a member of the scientific advisory boards of NGM Biopharmaceuticals and the Chan Zuckerberg Initiative, and an innovation partner at The Column Group.